Headshot of Jacob Glanville

Jacob Glanville

Centivax

Jacob Glanville is a serial entrepreneur and computational immuno-engineer. He is also the founder, CEO, & President of Centivax. He was formerly a Co-founder, CEO, and President of Distributed Bio, which he and his co-founders sold to Charles River Laboratories in 2020. During his time at Distributed Bio, he developed the core business model, research teams, and technologies that enabled the company to become profitable without investment.

As part of the acquisition agreement, he founded Centivax Inc and spun-out his assets in COVID-19 therapeutics, broad-spectrum vaccines, anti-venom antibodies, anti-wound pathogen antibodies, anti-CXCR5 autoimmunity therapeutics, and blood-brain barrier translation technologies into Centivax.

Jacob Glanville - Centivax - Part 4

How to Choose the Right Venture Capital Partner | Fundraising as “Dating” | Finding Proper Alignment & The Win-Win | VC Network as a “Polishing Engine”

Jacob Glanville - Centivax - Part 3

Building a Biotech without Venture Capital | Picking Lab Space & Company Growth | Equipment Leasing & Runway/Cash Flow Maximization | Process Drift & “The Respiration Model

Jacob Glanville - Centivax - Part 2

Creating Bioinformatic Tools | Innovation vs. Organization in Biotech Companies | Finding Excitement in Your Work | Tech Transfer & “Separation of Church and State

Jacob Glanville - Centivax - Part 1

Hospitality Industry’s Applied Lessons | The Benefits of Contingency Planning & Fair Negotiation | How to Seek Translational Skill Sets & Cross Training

Keep Up with The Biotech Startups Podcast

Start listening to TBSP episodes on your favorite platform.  Subscribe to stay up to date on new episodes.

A hand holding a bell